Contact

Myelin Forge Home About Services Research Overview Safety & Risks Next Steps for Research Contact Independent evidence context / 2026 Ibogaine and MS: What the Research Shows A clear look at a high-risk, experimental compound: what is known about multiple sclerosis (MS), what remains speculative, and why case reports are not proven care. Scientific restraint Safety first Evidence context Signal Evidence is early Experimental evidence Cardiac safety Case reports Controlled trials needed Experimental evidence 01 / Context Understanding multiple sclerosis (MS) Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, where the immune system mistakenly attacks the myelin sheath. The resulting inflammation, demyelination, and nerve damage can disrupt communication between the brain, spinal cord, and the rest of the body. Multiple sclerosis (MS) can manifest as relapse-remitting MS, secondary progressive MS, or primary progressive MS, with distinct disease progression patterns. Common symptoms include fatigue, numbness, weakness, vision problems, balance issues, and cognitive difficulties, all of which can affect quality of life. About 2.8 million people worldwide are estimated to live with multiple sclerosis (MS), and diagnosis commonly occurs between ages 20 and 50. The World Health Organization’s MS overview describes its long-term impact and the need for access to appropriate care. This is a neurodegenerative disease as well as an immune-mediated condition: neurological function may be affected by inflammation, lesions, and accumulated nerve damage over time. Existing therapies can reduce relapses or modify disease activity, but repairing a damaged myelin sheath remains a major research challenge. Multiple sclerosis (MS) is complex enough that a striking personal outcome cannot, by itself, show that a treatment changed the disease. 02 / Compound What is ibogaine? Ibogaine is a naturally occurring psychoactive compound and alkalo

Contact

A note before you reach out.